Fulcrum Therapeutics
MA · 4 filings, 2025
Lobbying spend · 2025
$160K
to shape legislation
About the organization
Losmapimod (GW856553X) is an investigational drug that reached stage III clinical trials for multiple medical conditions, but did not prove efficacy. It was most recently in development by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD). via Wikipedia ↗
1Lobbies on
Its filings list: Health Issues
2Through these firms · 1
THE MCMANUS GROUP
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5242A bill to provide for digital communication of prescribing information for drugs (including biological prod…
- HR 10033Rules for self-driving cars and emergency crews